Proactive Versus Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease: Is the Juice Worth the Squeeze?
Author:
Affiliation:
1. Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH
Publisher
Oxford University Press (OUP)
Subject
Gastroenterology,Immunology and Allergy
Link
http://academic.oup.com/ibdjournal/article-pdf/26/1/112/31495568/izz114.pdf
Reference9 articles.
1. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease;Feuerstein;Gastroenterology.,2017
2. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease;Vande Casteele;Gastroenterology.,2015
3. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s disease;D’Haens;Gastroenterology.,2018
4. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study;Vaughn;Inflamm Bowel Dis.,2014
5. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab;Papamichael;Clin Gastroenterol Hepatol.,2017
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Correlation between Therapeutic Drug Monitoring of Infliximab Serum Trough Levels and other Biomarkers in Iraqi Patients with Crohn's Disease;Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 );2024-03-24
2. The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn’s disease;Scandinavian Journal of Gastroenterology;2023-11-22
3. Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review;Pharmaceutics;2022-05-07
4. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues;Therapeutic Advances in Gastroenterology;2021-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3